{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:34:40Z","timestamp":1782506080270,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of next-generation sequencing, uncommon epidermal growth factor receptor mutations are more frequently discovered. Because seldom evaluated in clinical trials, their clinical significance and response on tyrosine kinase inhibitors are less well known.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 58-year-old Caucasian woman with no smoking history presented with advanced non-small cell lung cancer. Liver biopsy revealed an adenocarcinoma with a programmed death ligand-1 tumor proportion score of 30% and no common oncogenic driver mutations. A combination of chemotherapy and immunotherapy was started as first-line treatment. However, treatment was ceased after 18\u00a0weeks because of immune-related renal failure and disease progression. In the meantime, the next-generation sequencing results of the liver biopsy had revealed an exon 18 E709_T710delinsD mutation. Therefore, afatinib was administered, which was moderately tolerated with grade 2 paronychia and acneiform skin eruption. After 6\u00a0months, a partial response with ongoing decrease of the liver metastasis was retained.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Because of the lack of clinical trials, tumor heterogeneity, and a tyrosine kinase inhibitor affinity related to the different mutation types, it is difficult to predict the clinical outcome of tyrosine kinase inhibitor in uncommon mutations. Therefore, a therapeutic trial with tyrosine kinase inhibitor has to be considered, but the expected clinical response is lower than for common mutations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02994-0","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:06:09Z","timestamp":1637597169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Lander","family":"Van Acker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Vermaelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Surmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"2994_CR1","first-page":"CD1010383","volume":"5","author":"J Greenhalgh","year":"2016","unstructured":"Greenhalgh J, Dwan K, Boland A, et\u00a0al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016;5:CD1010383.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2994_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, FLAURA Investigators, et\u00a0al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"18","key":"2994_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et\u00a0al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"issue":"11","key":"2994_CR4","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","volume":"17","author":"J-Y Wu","year":"2011","unstructured":"Wu J-Y, Yu C-J, Chang Y-C, et\u00a0al. Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non\u2013small cell lung cancer. Clin Cancer Res. 2011;17(11):3812\u201321.","journal-title":"Clin Cancer Res"},{"issue":"27","key":"2994_CR5","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, et\u00a0al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2994_CR6","first-page":"113","volume":"45","author":"N Kutsuzawa","year":"2020","unstructured":"Kutsuzawa N, Takahashi F, Tomomatsu K, et\u00a0al. Successful treatment of a patient with lung adenocarcinoma harboring compound EGFR gene mutations, G719X and S768I, with Afatinib. Tokai J Exp Clin Med. 2020;45(3):113\u20136.","journal-title":"Tokai J Exp Clin Med"},{"issue":"7","key":"2994_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, AURA3 Investigators, et\u00a0al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"5","key":"2994_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","volume":"15","author":"JC Yang","year":"2020","unstructured":"Yang JC, Schuler M, Popat S, et\u00a0al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803\u201315.","journal-title":"J Thorac Oncol"},{"issue":"23","key":"2994_CR9","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","volume":"21","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Togashi Y, Yatabe Y, et\u00a0al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res. 2015;21(23):5305\u201313.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2994_CR10","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1097\/JTO.0b013e3182635ab4","volume":"7","author":"A Ackerman","year":"2012","unstructured":"Ackerman A, Goldstein MA, Kobayashi S, Costa DB. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):e19\u201320.","journal-title":"J Thorac Oncol"},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2017.04.016","volume":"109","author":"GM O'Kane","year":"2017","unstructured":"O\u2019Kane GM, Bradbury PA, Ronald Feld R, et\u00a0al. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017;109:137\u201344.","journal-title":"Lung Cancer"},{"issue":"1","key":"2994_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.cllc.2017.05.016","volume":"19","author":"S Pilotto","year":"2018","unstructured":"Pilotto S, Rossi A, Vaval\u00e0 T, et\u00a0al. Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study. Clin Lung Cancer. 2018;19(1):93\u2013104.","journal-title":"Clin Lung Cancer"},{"key":"2994_CR13","unstructured":"Catalogue of somatic mutations in cancer (COSMIC). https:\/\/cancer.sanger.ac.uk. Accessed 4 February 2021."},{"issue":"11","key":"2994_CR14","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/annonc\/mdx404","volume":"28","author":"C Leduc","year":"2017","unstructured":"Leduc C, Merlio JP, Besse B, et\u00a0al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017;28(11):2715\u201324.","journal-title":"Ann Oncol"},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2017.02.023","volume":"108","author":"U Ibrahim","year":"2017","unstructured":"Ibrahim U, Saqib A, Atallah JP. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. Lung Cancer. 2017;108:45\u20137.","journal-title":"Lung Cancer"},{"key":"2994_CR16","unstructured":"My Cancer genome. http:\/\/mycancergenome.org. Accessed 4 February 2021."},{"issue":"5","key":"2994_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH, Lim SH, An HJ, et\u00a0al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488\u201395.","journal-title":"J Clin Oncol"},{"key":"2994_CR18","doi-asserted-by":"crossref","unstructured":"Iwamoto Y, Ichihara E, Hara N, et\u00a0al. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. Jpn J Clin Oncol. 2019.","DOI":"10.1093\/jjco\/hyz086"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.2147\/OTT.S221638","volume":"12","author":"N An","year":"2019","unstructured":"An N, Wang H, Zhu H, et\u00a0al. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report. Onco Targets Ther. 2019;12:7399\u2013404.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"2994_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","volume":"11","author":"B Klughammer","year":"2016","unstructured":"Klughammer B, Brugger W, Cappuzzo F, et\u00a0al. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol Actions. 2016;11(4):545\u201355.","journal-title":"J Thorac Oncol Actions."},{"issue":"6","key":"2994_CR21","first-page":"GD01","volume":"14","author":"A Mehta","year":"2020","unstructured":"Mehta A, Batra U, Sharma M, et\u00a0al. Detection of rare targetable EGFR variant in metastatic non-small cell lung carcinoma by next generation sequencing: a case report. J Clin Diag Res. 2020;14(6):GD01\u20133.","journal-title":"J Clin Diag Res"},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.030","volume":"139","author":"AC Sousa","year":"2020","unstructured":"Sousa AC, Silveira C, Janeiro A, et\u00a0al. Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision. Lung Cancer. 2020;139:35\u201340.","journal-title":"Lung Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02994-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02994-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T16:15:47Z","timestamp":1637597747000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02994-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02994-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This publication was approved by the local ethics committee (University Hospitals Ghent).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"562"}}